Metabolic changes in autoimmune diseases

Current Drug Discovery Technologies

Volumn 6, Issue 4, 2009, Pages 256-261

  Seeger, Karsten ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Autoimmunity; Crohn's disease; Metabolomics; Rheumatoid arthritis

Indexed keywords

ALANINE; FEBRIFUGINE; GLUTAMINE; GLYCINE; GLYCOPROTEIN; HALOFUGINONE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; LACTIC ACID; LOW DENSITY LIPOPROTEIN; POLYUNSATURATED FATTY ACID; VERY LOW DENSITY LIPOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID METABOLISM; ANTIMALARIAL ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DIFFERENTIATION; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG STRUCTURE; ENTERITIS; GENETIC IDENTIFICATION; GENOMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOMODULATION; LACTATE BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MASS FRAGMENTOGRAPHY; METABOLOME; METABOLOMICS; METHODOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; WILD TYPE;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; METABOLOMICS; MODELS, BIOLOGICAL;

EID: 70449699790     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309789869074     Document Type: Review

References (42)

1. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: A platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1(2): 153-161 (Pubitemid 41646523)
2. Bollard ME, Stanley EG, Lindon JC, Nicholson JK, Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed 2005; 18(3): 143-162 (Pubitemid 40716122)
3. Ceglarek U, Leichtle A, Brügel M, et al. Challenges and developments in tandem mass spectrometry based clinical metabolomics. Mol Cell Endocrinol 2009; 301(1-2): 266-271
4. Shanaiah N, Zhang S, Desilva MA, Raftery D. NMR-based metabolomics for biomarker discovery. In: Biomarker Methods in Drug Discovery and Dev 2008; pp. 341-368
5. Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol 2008; 21(1): 9-27. (Pubitemid 351219705)
6. Pasikanti KK, Ho PC, Chan ECY. Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 871(2): 202-211
7. Lu X, Zhao X, Bai C, et al. LC-MS-based metabonomics analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 866(1-2): 64-76.
8. Weljie AM, Newton J, Mercier P, Carlson E, Slupsky CM. Targeted profiling: Quantitative analysis of 1H NMR metabolomics data. Anal Chem 2006; 78(13): 4430-4442
9. Araníbar N, Ott K-H, Roongta V, Mueller L. Metabolomic analysis using optimized NMR and statistical methods. Anal Biochem 2006; 355(1): 62-70. (Pubitemid 44041397)
10. Mo H, Raftery D. Improved residual water suppression: WET180. J Biomol NMR 2008; 41(2): 105-111
11. Mo H, Raftery D. Pre-SAT180, a simple and effective method for residual water suppression. J Magn Reson 2008; 190(1): 1-6. (Pubitemid 350235244)
12. Simpson AJ, Brown SA. Purge NMR: Effective and easy solvent suppression. J Magn Reson 2005; 175(2): 340-346
13. Lucas LH, Larive CK, Wilkinson PS, Huhn S. Progress toward automated metabolic profiling of human serum: Comparison of CPMG and gradient-filtered NMR analytical methods. J Pharm Biomed Anal 2005; 39(1-2): 156-163 (Pubitemid 41112132)
14. Zhang F, Brüschweiler R. Robust deconvolution of complex mixtures by covariance TOCSY spectroscopy. Angew Chem 2007; 119(15): 2693-2696 (Pubitemid 46973551)
15. Cui Q, Lewis IA, Hegeman AD, et al. Metabolite identification via the Madison Metabolomics Consortium Database. Nat Biotech 2008; 26(2): 162-164 (Pubitemid 351225941)
16. Wishart DS, Tzur D, Knox C, et al. HMDB: The Human Metabolome Database. Nucleic Acids Res 2007; 35(suppl-1): D521-26.
17. Wilson ID, Plumb R, Granger J, et al. HPLC-MS-based methods for the study of metabonomics. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 817(1): 67-76.
18. Lenz EM, Wilson ID. Analytical strategies in metabonomics. J Proteome Res 2006; 6(2): 443-458
19. Tukiainen T, Tynkkynen T, Mäkinen VP, et al. A multi-metabolite analysis of serum by 1H NMR spectroscopy: Early systemic signs of Alzheimer's disease. Biochem Biophys Res Commun 2008; 375(3): 356-361
20. Saude EJ, Obiefuna IP, Somorjai RL, et al. Metabolomic biomarkers in a model of asthma exacerbation: urine nuclear magnetic resonance. Am J Respir Crit Care Med 2009; 179(1): 25-34.
21. Barba I, Chatauret N, García-Dorado D, Córdoba J. A 1H nuclearmagnetic resonance-based metabonomic approach for grading hepatic encephalopathy and monitoring the e¡ects of therapeutic hypothermia in rats. Liver Int 2008; 28(8): 1141-1148
22. Mayr M, Chung Y-L, Mayr U, et al. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol 2005; 25(10): 2135-2142 (Pubitemid 41416312)
23. Luciani AM, Grande S, Palma A, et al. Characterization of 1H NMR detectable mobile lipids in cells from human adenocarcinomas. FEBS J 2009; 276(5): 1333-1346
24. Naughton D, Whelan M, Smith EC, et al. An investigation of the abnormal metabolic status of synovial fluid from patients with rheumatoid arthritis by high field proton nuclear magnetic resonance spectroscopy. FEBS Lett 1993; 317(1,2): 135-138 (Pubitemid 23043956)
25. Weljie AM, Dowlatabadi R, Miller BJ, Vogel HJ, Jirik FR. An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J Proteome Res 2007; 6(9): 3456-3464 (Pubitemid 47522736)
26. Zhang S, Nagana Gowda GA, Asiago V, et al. Correlative and quantitative 1H NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. Anal Biochem 2008; 383(1): 76-84.
27. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007; 6(2): 546-551 (Pubitemid 46340158)
28. Balasubramanian K, Kumar S, Singh RR, et al. Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: An in vitro proton magnetic resonance spectroscopy study. Magn Reson Imaging 2009; 27(1): 79-86.
29. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin- 10-deficient mice develop chronic enterocolitis. Cell 1993; 75(2): 263-274 (Pubitemid 23320290)
30. Martin F-PJ, Rezzi S, Montoliu I, et al. Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice. J Proteome Res 2009; 8(5): 2376-2387
31. Murdoch TB, Fu H, MacFarlane S, et al. Urinary metabolic profiles of inflammatory bowel disease in Interleukin-10 gene-deficient mice. Anal Chem 2008; 80(14): 5524-5531
32. Lin HM, Edmunds SJ, Helsby NA, Ferguson LR, Rowan DD. Nontargeted urinary metabolite profiling of a mouse model of Crohn's disease. J Proteome Res 2009; 8(4): 2045-2057
33. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: Much ado about IDO. Trends Immunol 2003; 24(5): 242-248
34. Zhong Z, Wheeler MD, Li X, et al. L-Glycine: A novel antiinflammatory, immunomodulatory, and cytoprotective agent. Curr Opin Clin Nutr Metab Care 2003; 6(2): 229-240 (Pubitemid 40674528)
35. Li X, Bradford BU, Wheeler MD, et al. Dietary glycine prevents peptidoglycan polysaccharide-induced reactive arthritis in the rat: Role for glycine-gated chloride channel. Infect Immun 2001; 69(9): 5883-5891 (Pubitemid 32786529)
36. Jiang N, Yan X, Zhou W, et al. NMR-based metabonomic investigations into the metabolic profile of the senescence-accelerated mouse. J Proteome Res 2008; 7(9): 3678-3686
37. Sundrud MS, Koralov SB, Feuerer M, et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 2009; 324(5932): 1334-1338
38. Jiang S, Zeng Q, Gettayacamin M, et al. Antimalarial activities and therapeutic properties of febrifugine analogs. Antimicrob Agents Chemother 2005; 49(3): 1169-1176 (Pubitemid 40327741)
39. Pines M, Nagler A. Halofuginone: A novel antifibrotic therapy. Gen Pharmacol 1998; 30(4): 445-450
40. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17- producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6(11): 1123-1132
41. Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13(2): 139-145
42. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19(3): 281-286